1. Carter J, Saunders V. Virology: Principles and Applications: John Wiley & Sons, Chichester; 2007.
2. Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WLJ. Development of stable influenza vaccine powder formulations: Challenges and possibilities. Pharm Res 2008; 25:1256-1273.
3. Smith DM, Simon JK, Baker JR Jr. Applications of nanotechnology for immunology. Nat Rev Immunol 2013; 13:592-605.
4. Tafaghodi M, Eskandari M, Kharazizadeh M, Khamesipour A, Jaafari MR. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins. Trop Biomed 2010; 27:639-650.
5. Mohaghegh M, Tafaghodi M. Dextran microspheres could enhance immune responses against PLGA nanospheres encapsulated with tetanus toxoid and Quillaja saponins after nasal immunization in rabbit. Pharm Dev Technol 2011; 16:36-43.
6. Babapoor S, Neef T, Mittelholzer C, Girshick T, Garmendia A, Shang H,
et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Res Treat 2011; 2011:126794.
7. Keijzer C, Slütter B, van der Zee R, Jiskoot W, van Eden W, Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS One 2011; 6:e26684.
8. Zaman M, Chandrudu S, Toth I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res 2013; 3:100-109.
9. Dehghan S, Tavassoti Kheiri M, Tabatabaiean M, Darzi S, Tafaghodi M. Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization. Arch Pharm Res 2013; 36:981-992.
Mohajer et al PLGA nanospheres promising nasal delivery systems Iran J Basic Med Sci, Vol. 17, No. 9, Sep 2014 5
10. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002; 82:105-114.
11. Alpar HO, Almeida AJ. Identification of some of the physico-chemical characteristics of microspheres which influence the induction of the immune response following mucosal delivery. Eur J Pharm Biopharm 1994; 40:198-202.
12. Khameneh B, Momen-Nejad M, Tafaghodi M.
In vivo evaluation of mucoadhesive properties of nanoliposomal formulations upon coating with trimethylchitosan polymer. Nanomed J 2014; 1:147-154.
13. Yang L, Chen L, Zeng R, Li C, Qiao R, Hu L,
et al. Synthesis, nanosizing and in vitro drug release of a novel anti-HIV polymeric prodrug: Chitosan-O-isopropyl-5′-O-d4T monophosphate conjugate. Bioorg Med Chem 2010; 18:117-123.
14. Xue SW. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers: Part III. Drug delivery application. Artif Cells Blood Substit Immobil Biotechnol 2004; 32:575-591.
15. Benelli P, Conti B, Genta I, Costantini M, Montanari L. Clonazepam microencapsulation in poly-D,L-lactide-co-glycolide microspheres. J Microencapsul 1998; 15:431-443.